Market Overview

Veloxis Pharmaceuticals Envarsus Granted Orphan Drug Status by FDA for Kidney Transplant Rejection Prophylaxis

Veloxis Pharmaceuticals (OTC: VLCYF), today announced that Envarsus® was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients receiving allogenic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. Envarsus® is Veloxis' once-daily formulation of tacrolimus employing the company's proprietary MeltDose® technology.

See full press release

Posted-In: News Guidance Contracts FDA Management Global

 

Related Articles (LFCYF)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters